Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3753 - Phase II clinical trial of peptide vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS.


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Immunotherapy;  Head and Neck Cancers




Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376


Y. YOSHITAKE1, D. Fukuma2, M. Hirayama2, H. Nakayama2, H. Ogi2, M. Shinohara2

Author affiliations

  • 1 Department Of Oral & Maxillofacial Surgery, Graduate School of Medical Sciences, Kumamoto University, 860-8556 - Kumamoto City/JP
  • 2 Department Of Oral & Maxillofacial Surgery, Kumamoto University, 860-8556 - Kumamoto/JP


Abstract 3753


The peptides derived from ideal cancer-testis antigens, including LY6K, CDCA1 and IMP3 (identified using genome-wide cDNA microarray analyses), were utilized in immunotherapy for head and neck squamous cell cancer (HNSCC). In this trial, we analyzed the immune response to and safety and efficacy of vaccine therapy.


A total of 40 patients with advanced HNSCC were enrolled in this trial of peptide vaccine therapy, and the OS, PFS and immunological response were evaluated using enzyme-linked ImmunoSpot (ELISPOT) and pentamer assays. The peptides were subcutaneously administered weekly with IFA. The primary endpoints were evaluated based on differences between HLA-A*2402-positive (A24(+)) patients treated with peptide vaccine therapy and –negative (A24(-)) patients treated without peptide vaccine therapy among those with advanced HNSCC.


Our cancer vaccine therapy was well tolerated. The OS of the A24(+)v accinated group (n = 40) was statistically significantly longer than that of the A24(-) group (n = 18) (MST 4.9 vs. 3.5 month, respectively, p 


The immune response induced by this peptides vaccine may improve the prognosis of patients with advanced HNSCC.

Clinical trial identification

Legal entity responsible for the study

Yoshihiro Yoshitake




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.